Raphael Pharmaceutical (RAPH) Retained Earnings (2020 - 2025)

Raphael Pharmaceutical (RAPH) has 6 years of Retained Earnings data on file, last reported at -$10.2 million in Q4 2025.

• For the quarter ending Q4 2025, Retained Earnings fell 14.39% year-over-year to -$10.2 million; the trailing twelve-month figure through Dec 2025 stood at -$10.2 million (down 14.39% YoY), and the FY2025 full-year result was -$10.2 million, down 14.39% from the prior year.
• Retained Earnings retreated to -$10.2 million in Q4 2025, from -$9.9 million in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $7.2 million in Q3 2023 to a low of -$10.2 million in Q4 2025.
• A 5-year average of -$3.3 million and a median of -$6.7 million in 2022 frame the typical range for Retained Earnings.
• Across the five-year window, Retained Earnings soared 355.51% in 2021 and tumbled 326.12% in 2022, its largest moves.
• Tracing RAPH's Retained Earnings over 5 years: stood at $2.7 million in 2021, then slumped by 326.12% to -$6.0 million in 2022, then slipped by 22.3% to -$7.4 million in 2023, then dropped by 20.61% to -$8.9 million in 2024, then retreated by 14.39% to -$10.2 million in 2025.
• Business Quant data shows RAPH's Retained Earnings at -$10.2 million in Q4 2025, -$9.9 million in Q3 2025, and -$9.6 million in Q2 2025.